WANY
CORT icon

Wealthspire Advisors (New York)’s Corcept Therapeutics CORT Stock Holding History

Wealthspire Advisors (New York)’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,864
Closed -$321K – 1410
2025
Q3 		$321K Sell
3,864
-102
-3% -$7.38K ﹤0.01% 639
2025
Q2 		$291K Sell
3,966
-47
-1% -$3.41K ﹤0.01% 677
2025
Q1 		$458K Buy
+4,013
New +$244K ﹤0.01% 532

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wealthspire Advisors (New York)'s CORT Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 3,864 shares — an estimated $321K sold.

Wealthspire Advisors (New York) first reported a position in CORT in Q1 2025 and held it in 3 quarters. The position peaked at $458K in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 3,864 Corcept Therapeutics shares in Q4 2025, an estimated $321K.
  • Wealthspire Advisors (New York) first reported a position in Corcept Therapeutics in Q1 2025 and held it in 3 quarters.
  • Wealthspire Advisors (New York)'s Corcept Therapeutics position peaked at $458K in Q1 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.